LILRB2 and hepatocellular carcinoma: We demonstrate that ANGPTL8 interacts with the LILRB2/PIRB receptor to execute crucial activities that promote tumor cell proliferation and modulate macrophage polarization and T-cell infiltration to facilitate the immune escape of tumorigenic cells (Fig. 6F), making ANGPTL8 an attractive therapeutic target for treating HCC.